Research Center on Thromboembolic Disorders and Antithrombotic Therapies, University of Insubria, Varese, Italy.
Thromb Res. 2012 Apr;129 Suppl 1:S93-6. doi: 10.1016/S0049-3848(12)70025-7.
Splanchnic vein thrombosis (SVT) is a rather heterogeneous disease which involve one or more abdominal veins draining from different organs, including small and large bowel, liver, spleen and pancreas, and it may be associated with a wide spectrum of underlying disorders, either local or systemic. The role of new risk factors for SVT, including the JAK2 V617F mutation and the paroxysmal nocturnal hemoglobinuria clone, has been highlighted in recent years. The clinical presentations of SVT are variable and, not uncommonly, may include the concomitant presence of extensive thrombosis and gastrointestinal bleeding, thus representing a clinical challenge for treatment decisions. High quality evidence on the acute and long-term management is substantially lacking, thus requiring further research on SVT.
内脏静脉血栓形成（SVT）是一种相当异质性的疾病，涉及一条或多条来自不同器官的腹部静脉，包括小肠、大肠、肝脏、脾脏和胰腺，它可能与广泛的局部或系统性基础疾病相关。近年来，新的 SVT 风险因素，包括 JAK2 V617F 突变和阵发性夜间血红蛋白尿克隆，其作用已得到强调。SVT 的临床表现多种多样，而且并不罕见，可能包括广泛血栓形成和胃肠道出血同时存在，因此对治疗决策构成了临床挑战。关于急性和长期管理的高质量证据实际上非常缺乏，因此需要对 SVT 进行进一步的研究。
